FDA to require vision loss warning on GLP-1 drug labels

The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.

KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.